GSPT1 may control the activity of CyclinD1, CDK4, and CDK6 by binding to TRIM4, an E3 ubiquitin ligase, to mediate GSK‐3β degradation, and lead to an indirect impact on CyclinE and CDK2 expression through p21 and p27, which ultimately governs the transition of colon cancer cells from the G1 phase to S phase, facilitating tumor advancement.[19, 78] However, no in‐depth evidence of GSPT1 on GSK‐3β in cancer through TRIM4 has been revealed. This evidence concerns the gene TRIM4 and malignant colon neoplasm.